{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "BASIL-2: A Randomised Controlled Trial of Revascularization Strategies in CLTI"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "BASIL-2 was an open-label, multicentre, phase 3 randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "conducted in 41 vascular surgery units across the UK, Sweden, and Denmark"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned in a 1:1 ratio to either VB-first or BET-first strategies"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to assess the cost-effectiveness and cost-utility of a vein bypass (VB) first versus a best endovascular treatment (BET) first revascularization strategy"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was amputation-free survival (AFS) over a 2- to 7-year follow-up period"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 3,
        "evidence": "BASIL-2 was an open-label, multicentre, phase 3 randomised controlled trial"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 345 participants were randomised (172 to VB-first, 173 to BET-first) between July 2014 and November 2020"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The analysis was conducted on an intention-to-treat basis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "BET-first showing lower costs (\u2013\u00a32,524, 95% CI \u2013\u00a35,845 to \u00a31,132). BET-first was more effective, yielding additional amputation-free life years (AFLYs) (0.429, 95% CI 0.03 to 0.88) and quality-adjusted life years (QALYs) (0.016, 95% CI \u20130.08 to 0.12)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported in either group"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered with ISRCTN27728689"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by the NIHR HTA"
      }
    },
    "total_score": 25,
    "max_score": 25
  },
  "model": "gpt-4o"
}